EU Regulatory News Round Up: NSAIDs During Pregnancy, Estragole Excipients, ePIs
Executive Summary
CMDh receives applications to change how NSAIDs are recommended for use during pregnancy; HMPC warns against use of estragole-containing excipients in herbals; EMA adopts new EU common standard for electronic product information on medicines marketed within the region.
You may also be interested in...
AESGP Annual Meeting, Day 2 (Part 2): Can Regulation Be A Catalyst For Innovation?
Regulation should be seen as a spur to creativity rather than a burden, suggest panellists during the second session of the AESGP's 58th Annual Meeting in Madrid, Spain. Sanofi Consumer Healthcare boss Julie van Ongevalle also makes the case for electronic patient information leaflets as a way to learn from the pandemic, which she describes as the greatest constraint the world has experienced in recent history.
Self-Care Key To EU Pharmaceutical Strategy, Says Rapporteur
Only with help of the non-prescription medicines sector will the aims of the new European Union pharmaceutical strategy be achieved, argues MEP and rapporteur Dolors Montserrat at the AESGP Annual Meeting.
Approvals For Stronger NSAIDs Label Warning About Risks During Late Pregnancy Begin In US
FDA since late October has sent approvals to firms which had submitted proposals for updates under the “If pregnant or breast-feeding” warning on their OTC NDAID DFls. First approval, dated 21 October, went to Bionpharma for its 200-mg ibuprofen tablets it provides for private label and store brand customers.